717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Bibliographic Details
Main Authors:	Caius Radu, Mark Salvati, Julie Bailis, Katharina Lueckerath, Kyle Current, Johannes Czernin
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Streamlined Schemes for Dosimetry of <sup>177</sup>Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
by: Jens Kurth, et al.
Published: (2021-08-01)

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
by: Daniel Groener, et al.
Published: (2021-07-01)

PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties
by: Piotr Garnuszek, et al.
Published: (2021-03-01)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
by: Wallace Jones, et al.
Published: (2020-05-01)

Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer
by: Gabriele Birindelli, et al.
Published: (2021-07-01)

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
by: Finn Edler von Eyben, et al.
Published: (2020-11-01)

340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
by: Ben Tran, et al.
Published: (2020-11-01)

Metal-Based PSMA Radioligands
by: Eleni Gourni, et al.
Published: (2017-03-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ai, S., et al.
Published: (2022)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
by: Philipp E. Hartrampf, et al.
Published: (2021-08-01)

Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
by: Madhav Prasad Yadav, et al.
Published: (2021-01-01)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
by: Zool Hilmi Awang, et al.
Published: (2018-05-01)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
by: Caliebe, A., et al.
Published: (2022)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)
by: Joshi, Jay
Published: (2020)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer
by: Walker, Natalie
Published: (2019)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Recent Progress of Functionalized PSMA in Radionuclide Targeted Therapy for Prostate Cancer
by: REN Ya'nan, et al.
Published: (2020-12-01)

Salvage therapies for PSMA PET-positive nodal recurrent prostate cancer
by: A. Kretschmer, et al.
Published: (2020-07-01)

Editor’s Pick: PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy
by: Wei Jin, et al.
Published: (2016-04-01)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
by: Katharina Lückerath, et al.
Published: (2018-10-01)

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
by: Friedman, K.P, et al.
Published: (2022)

Development of a Novel PSMA - Driven Gene Therapy for the Treatment of Prostate Cancer
by: Page, N. L.
Published: (2010)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
by: Mohamed El Fakiri, et al.
Published: (2021-08-01)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
by: Judith Stangl-Kremser, et al.
Published: (2021-08-01)

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
by: Ameya D Puranik, et al.
Published: (2021-07-01)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
by: Magdalena Staniszewska, et al.
Published: (2021-07-01)

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
by: Jeremie Calais, et al.
Published: (2019-01-01)

Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
by: Zhu Q, et al.
Published: (2011-08-01)

Development, Characterization, and Evaluation of PSMA-Targeted Glycol Chitosan Micelles for Prostate Cancer Therapy
by: Jing Xu, et al.
Published: (2014-01-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy
by: Ashwin Singh Parihar, et al.
Published: (2021-01-01)

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

<sup>177</sup>Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Finn E. von Eyben, et al.
Published: (2021-08-01)

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
by: Jeremie Calais, et al.
Published: (2021-05-01)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
by: Jeremie Calais, et al.
Published: (2019-01-01)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Asta Juzeniene, et al.
Published: (2021-02-01)

Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?
by: Ramin Alipour, et al.
Published: (2019-09-01)